References
- Akhtar M., Corina D., Miller S., Shyadehi A. Z., Wright J. N. Mechanism of the acyl‐carbon cleavage and related reactions catalyzed by multifunctional P‐450s: studies on cytochrome P45017α. Biochemistry 1994; 33: 4410–4418, [PUBMED], [INFOTRIEVE]
- Aldridge S. Astex Technology applies fragment‐based discovery. Genet. Eng. News 2003; 23: 76–77
- Anandatheerthavarada H. K., Addya S., Mullick J., Avadhani N. G. Interaction of adrenodoxin with P4501A1 and its truncated form P450MT2 through different domains: differential modulation of enzyme activities. Biochemistry 1998; 37: 1150–1160, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Anders M. Enhancement and inhibition of drug metabolism. Annu. Rev. Pharmacol. 1971; 11: 37–56, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ariyoshi N., Miyamoto M., Umetsu Y., Kunitoh H., Dosaka‐Akita H., Sawamura Y., Yokota J., Nemoto N., Sato K., Kamataki T. Genetic polymorphism of CYP2A6 gene and tobacco—induced lung cancer risk in male smokers. Cancer Epidemiol. Biomark. Prev. 2002; 11: 890–894, [CSA]
- Armstrong R. N., Pinto‐Coelho C., Ryan D. E., Thomas P. E., Levin W. On the glycosylation state of five rat hepatic microsomal cytochrome P‐450 isozymes. J. Biol. Chem. 1983; 258: 2106–2108, [PUBMED], [INFOTRIEVE]
- Auchus R. J., Lee T. C., Miller W. L. Cytochrome b5 augments the 17,20‐lyase activity of human P450c17 without direct electron transfer. J. Biol. Chem. 1998; 273: 3158–3165, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Auclair K., Hu Z., Little D. M., Ortiz de Montellano P. R., Groves J. T. Revisiting the mechanism of P450 enzymes with the radical clocks norcarane and spiro[2,5]octane. J. Am. Chem. Soc. 2002; 124: 6020–6027, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Aust S. D., Roerig D. L., Pederson T. C. Evidence for superoxide generation by NADPH‐cytochrome c reductase of rat liver microsomes. Biochem. Biophys. Res. Commun. 1972; 47: 1133–1137, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Axelrod J. The enzymatic deamination of amphetamine. J. Biol. Chem. 1955; 214: 753–763, [PUBMED], [INFOTRIEVE]
- Bachmann C., Bickel M. H. History of drug metabolism: the first half of the 20th century. Drug Metab. Rev. 1986; 16: 185–253
- Backes W. L., Eyer C. S. Cytochrome P‐450 LM2 reduction: substrate effects on the rate of reductase‐LM2 association. J. Biol. Chem. 1989; 264: 6252–6259, [PUBMED], [INFOTRIEVE]
- Backes W. L., Batie C. J., Cawley G. F. Interactions among P450 enzymes when combined in reconstituted systems: formation of a 2B4‐1A2 complex with a high affinity for NADPH‐cytochrome P450 reductase. Biochemistry 1998; 37: 12852–12859, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Barnes H. J. Maximizing expression of eukaryotic cytochrome P450s in Escherichia coli. Methods Enzymol. 1996; 272: 3–14, [PUBMED], [INFOTRIEVE]
- Bax A. Weak alignment offers new NMR opportunities to study protein structure and dynamics. Protein Sci. 2003; 12: 1–16, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bell L. C., Guengerich F. P. Oxidation kinetics of ethanol by human cytochrome P450 2E1. Rate‐limiting product release accounts for effects of isotopic hydrogen substitution and cytochrome b5 on steady‐state kinetics. J. Biol. Chem. 1997; 272: 29643–29651, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bell‐Parikh L. C., Guengerich F. P. Kinetics of cytochrome P450 2E1‐catalyzed oxidation of ethanol to acetic acid via acetaldehyde. J. Biol. Chem. 1999; 274: 23833–23840, [CROSSREF]
- Bell S. G., Chen X., Sowden R. J., Xu F., Williams J. N., Wong L. L., Rao Z. Molecular recognition in (+)‐α‐pinene oxidation by cytochrome P450cam. J. Am. Chem. Soc. 2003; 125: 705–714, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Benetton S., Kameoka J., Tan A., Wachs T., Craighead H., Henion J. D. Chip‐based P450 drug metabolism coupled to electrospray ionization‐mass spectrometry detection. Anal. Chem. 2003; 75: 6430–6436, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Boddupalli S. S., Estabrook R. W., Peterson J. A. Fatty acid monooxygenation by cytochrome P‐450BM‐3. J. Biol. Chem. 1990; 265: 4233–4239, [PUBMED], [INFOTRIEVE]
- Bradfield C. A. Induction of P450 enzymes: receptors. Cytochrome P450: Structure, Mechanism, and Biochemistry3rd ed., P. R Ortiz de Montellano. Plenum Press, New York 2004, in press
- Bradrick T. D., Beechem J. M., Howell E. E. Unusual binding stoichiometries and cooperativity are observed during binary and ternary complex formation in the single active pore of R67 dihydrofolate reductase, a D2 symmetric protein. Biochemistry 1996; 35: 11414–11424, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bradshaw W. H., Conrad H. E., Corey E. J., Gunsalus I. C., Lednicer D. Degradation of (+)‐camphor. J. Am. Chem. Soc. 1959; 81: 5007
- Buening M. K., Fortner J. G., Kappas A., Conney A. H. 7,8‐Benzoflavone stimulates the metabolic activation of aflatoxin B1 to mutagens by human liver. Biochem. Biophys. Res. Commun. 1978; 82: 348–355, [PUBMED], [INFOTRIEVE]
- Buters J. T.M., Sakai S., Richter T., Pineau T., Alexander D. L., Savas U., Doehmer J., Ward J. M., Jefcoate C. R., Gonzalez F. J. Cytochrome P450 CYP1B1 determines susceptibility to 7,12‐dimethylbenz[a]anthracene‐induced lymphomas. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 1977–1982, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Capdevila J. H., Wei S., Helvig C., Falck J. R., Belosludtsev Y., Truan G., Graham‐Lorence S. E., Peterson J. A. The highly stereoselective oxidation of polyunsaturated fatty acids by cytochrome P450BM‐3. J. Biol. Chem. 1996; 271: 22663–22671, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Cawley G. F., Batie C. J., Backes W. L. Substrate‐dependent competition of different P450 isozymes for limiting NADPH‐cytochrome P450 reductase. Biochemistry 1995; 34: 1244–1247, [PUBMED], [INFOTRIEVE]
- Chen S., Shively J. E., Nakajin S., Shinoda M., Hall P. F. Amino terminal sequence analysis of human placenta aromatase. Biochem. Biophys. Res. Commun. 1986; 135: 713–719, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chen X., Christopher A., Jones J. P., Bell S. G., Guo Q., Xu F., Rao Z., Wong L. L. Crystal structure of the F87W/Y96F/V247L mutant of cytochrome P‐450cam with 1,3,5‐trichlorobenzene bound and further protein engineering for the oxidation of pentachlorobenzene and hexachlorobenzene. J. Biol. Chem. 2002; 277: 37519–37526, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chen S., Zhang F., Sherman M. A., Kijima I., Cho M., Yuan Y. C., Toma Y., Osawa Y., Zhou D., Eng E. T. Structure‐function studies of aromatase and its inhibitors: a progress report. J. Steroid Biochem. Mol. Biol. 2003; 86: 231–237, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chung B., Matteson K. J., Voutilainen R., Mohandas T. K., Miller W. L. Human cholesterol side‐chain cleavage enzyme, P450scc: cDNA cloning, assignment of the gene to chromosome 15, and expression in the placenta. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 8962–8966, [PUBMED], [INFOTRIEVE], [CSA]
- Cinti D. L. Agents activating the liver microsomal mixed function oxidase system. Pharmacol. Ther. 1978; 2: 727–749
- Cleland W. W., O'Leary M. H., Northrop D. B. Isotope Effects on Enzyme‐Catalyzed Reactions. University Park Press, Baltimore 1977
- Cole P. A., Robinson C. H. Mechanistic studies on a placental aromatase model reaction. J. Am. Chem. Soc. 1991; 113: 8130–8137
- Conney A. H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowes memorial lecture. Cancer Res. 1982; 42: 4875–4917, [PUBMED], [INFOTRIEVE]
- Conney A. H., Miller E. C., Miller J. A. The metabolism of methylated aminoazo dyes.V. Evidence for induction of enzyme synthesis in the rat by 3‐methylcholanthrene. Cancer Res. 1956; 16: 450–459, [PUBMED], [INFOTRIEVE]
- Conti A., Bickel M. H. History of drug metabolism: discoveries of the major pathways in the 19th century. Drug Metab. Rev. 1977; 6: 1–50
- Correia M. A. Hepatic cytochrome P450 degradation: mechanistic diversity of the cellular sanitation brigade. Drug Metab. Rev. 2003; 35: 107–143, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dabrowski M. J., Schrag M. L., Wienkers L. C., Atkins W. M. Pyrene–pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J. Am. Chem. Soc. 2002; 124: 11866–11867, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Delesque‐Touchard N., Park S. H., Waxman D. J. Synergistic action of hepatocyte nuclear factors 3 and 6 on CYP2C12 gene expression and suppression by growth hormone‐activated—STAT5b. Proposed model for female‐specific expression of CYP2C12 in adult rat liver. J. Biol. Chem. 2000; 275: 34173–34182, [CROSSREF]
- d'Errico A., Taioli E., Chen X., Vineis P. Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. BioMarkers 1996; 1: 149–173
- Distlerath L. M., Guengerich F. P. Enzymology of human liver cytochromes P‐450. Mammalian Cytochromes P‐450, Volume 1, F. P. Guengerich. CRC Press, Boca Raton, FL 1987; 133–198
- Distlerath L. M., Reilly P. E.B., Martin M. V., Davis G. G., Wilkinson G. R., Guengerich F. P. Purification and characterization of the human liver cytochromes P‐450 involved in debrisoquine 4‐hydroxylation and phenacetin O‐deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 1985; 260: 9057–9067, [PUBMED], [INFOTRIEVE]
- Dolphin D., Felton R. H. The biochemical significance of porphyrin π cation radicals. Acc. Chem. Res. 1974; 7: 26–32
- Domanski T. L., He Y. A., Khan K. K., Roussel F., Wang Q., Halpert J. R. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 2001; 40: 10150–10160, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Dorfman R., Cook J. W., Hamilton J. B. Conversion by the human of the testis hormone, testosterone, into the urinary androgen, androsterone. J. Biol. Chem. 1939; 130: 285–295
- Dunn A. R., Dmochowski I. J., Bilwes A. M., Gray H. B., Crane B. R. Probing the open state of cytochrome P450cam with ruthenium‐linker substrates. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 12420–12425, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Egnell A. C., Eriksson C., Albertson N., Houston B., Boyer S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J. Pharmacol. Exp. Ther. 2003; 307: 878–887, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Estabrook R. W. A passion for P450s (rememberances of the early history of research on cytochrome P450). Drug Metab. Dispos. 2003; 31: 1461–1473, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Estabrook R. W., Lindenlaub E. The induction of drug metabolism. Symposia Medica Hoechst 14, R. W. Estabrook, E. Lindenlaub. Schattauer Verlag, F.K., Stuttgart 1979
- Estabrook R. W., Cooper D. Y., Rosenthal O. The light reversible carbon monoxide inhibition of the steroid C21‐hydroxylase system of the adrenal cortex. Biochem. Zeit. 1963; 338: 741–755
- Evans W. E., Relling M. V. Pharmacogenomics: translating function genomics into rational therapeutics. Science 1999; 286: 487–491, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Evenas J., Tugarinov V., Skrynnikov N. R., Goto N. K., Muhandiram R., Kay L. E. Ligand‐induced structural changes to maltodextrin‐binding protein as studied by solution NMR spectroscopy. J. Mol. Biol. 2001; 309: 961–974, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fedorov R., Ghosh D. K., Schlichting I. Crystal structures of cyanide complexes of P450cam and the oxygenase domain of inducible nitric oxide synthase‐structural models of the short‐lived oxygen complexes. Arch. Biochem. Biophys. 2003; 409: 25–31, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fersht A. Structure and Mechanism in Protein Science. Freeman, New York 1999
- Frey P. A. Radicals in enzymatic reactions. Curr. Opin. Chem. Biol. 1997; 1: 347–356, [PUBMED], [INFOTRIEVE], [CSA]
- Galetin A., Clarke S. E., Houston J. B. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab. Dispos. 2002; 30: 1512–1522, [PUBMED], [INFOTRIEVE], [CSA]
- Gelboin H. V. Carcinogens, enzyme induction and gene action. Adv. Cancer. Res. 1967; 10: 1–81, [PUBMED], [INFOTRIEVE]
- Gillette J. R. Insights into deuterium isotope effects on the metabolism of steroid hormones and foreign compounds by cytochrome P‐450 enzymes. Life Sci. 1991; 49: 1–14, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gillette J. R., Darbyshire J. F., Sugiyama K. Theory for the observed isotope effects on the formation of multiple products by different kinetic mechanisms of cytochrome P450 enzymes. Biochemistry 1994; 33: 2927–2937, [PUBMED], [INFOTRIEVE]
- Glieder A., Farinas E. T., Arnold F. H. Laboratory evolution of a soluble, self‐sufficient, highly active alkane hydroxylase. Nat. Biotechnol. 2002; 20: 1135–1139, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gonzalez F. J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 1989; 40: 243–288
- Gonzalez F. J., Kimura S. Study of P450 function using gene knockout and transgenic mice. Arch. Biochem. Biophys. 2003; 409: 153–158, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gonzalez F. J., Skoda R. C., Kimura S., Umeno M., Zanger U. M., Nebert D. W., Gelboin H. V., Hardwick J. P., Meyer U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442–446, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Goodwin B., Gauthier K. C., Umetani M., Watson M. A., Lochansky M. I., Collins J. L., Leitersdorf E., Mangelsdorf D. J., Kliewer S. A., Repa J. J. Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 223–228, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gorsky L. D., Coon M. J. Effects of conditions for reconstitution with cytochrome b5 on the formation of products in cytochrome P‐450‐catalyzed reactions. Drug Metab. Dispos. 1986; 14: 89–96, [PUBMED], [INFOTRIEVE]
- Groves J. T., McClusky G. A. Aliphatic hydroxylation via oxygen rebound: oxygen transfer catalyzed by iron. J. Am. Chem. Soc. 1976; 98: 859–861
- Groves J. T., McClusky G. A., White R. E., Coon M. J. Aliphatic hydroxylation by highly purified liver microsomal cytochrome P‐450: evidence for a carbon radical intermediate. Biochem. Biophys. Res. Commun. 1978; 81: 154–160, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Guengerich F. P. Separation and purification of multiple forms of microsomal cytochrome P‐450. Partial characterization of three apparently homogeneous cytochromes P‐450 prepared from livers of phenobarbital‐ and 3‐methylcholanthrene‐treated rats. J. Biol. Chem. 1978; 253: 7931–7939, [PUBMED], [INFOTRIEVE]
- Guengerich F. P. Roles of cytochrome P‐450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 1988; 48: 2946–2954, [PUBMED], [INFOTRIEVE]
- Guengerich F. P. Introduction and historical perspective. Biotransformation, Vol. 3, Comprehensive Toxicology, F. P. Guengerich. Elsevier Science Ltd., Oxford 1997; 1–6
- Guengerich F. P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001a; 14: 611–650, [PUBMED], [INFOTRIEVE], [CSA]
- Guengerich F. P. Reflections: forging the links between metabolism and carcinogenesis. Mutat. Res. 2001b; 488: 195–209, [PUBMED], [INFOTRIEVE], [CSA]
- Guengerich F. P. Cytochrome P450 enzymes in the generation of commercial products. Nat. Rev., Drug Discov. 2002a; 1: 359–366, [CROSSREF], [CSA]
- Guengerich F. P. Rate‐limiting steps in cytochrome P450 catalysis. Biol.Chem. 2002b; 383: 1553–1564, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Guengerich F. P. Cytochrome P450s, drugs, and diseases. Mol. Interv. 2003; 3: 8–18, [CROSSREF]
- Guengerich F. P. Human cytochrome P450 enzymes and drug metabolism. Cytochrome P450: Structure, Mechanism, and Biochemistry3rd Ed., P. R. Ortiz de Montellano. Plenum Press, New York 2004, in press
- Guengerich F. P., Johnson W. W. Kinetics of ferric cytochrome P450 reduction by NADPH‐cytochrome P450 reductase: rapid reduction in absence of substrate and variations among cytochrome P450 systems. Biochemistry 1997; 36: 14741–14750, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Guengerich F. P., Macdonald T. L. Chemical mechanisms of catalysis by cytochromes P‐450: a unified view. Acc. Chem. Res. 1984; 17: 9–16, [CSA]
- Guengerich F. P., Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P‐450 enzymes. Chem. Res. Toxicol. 1991; 4: 391–407, [PUBMED], [INFOTRIEVE], [CSA]
- Guengerich F. P., Martin M. V., Beaune P. H., Kremers P., Wolff T., Waxman D. J. Characterization of rat and human liver microsomal cytochrome P‐450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 1986; 261: 5051–5060, [PUBMED], [INFOTRIEVE]
- Guengerich F. P., Peterson L. A., Böcker R. H. Cytochrome P‐450‐catalyzed hydroxylation and carboxylic acid ester cleavage of Hantzsch pyridine esters. J. Biol. Chem. 1988; 263: 8176–8183, [PUBMED], [INFOTRIEVE]
- Guengerich F. P., Bell L. C., Okazaki O. Interpretations of cytochrome P450 mechanisms from kinetic studies. Biochimie 1995; 77: 573–580, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Guengerich F. P., Gillam E. M. J., Shimada T. New applications of bacterial systems to problems in toxicology. CRC Crit. Rev. Toxicol. 1996; 26: 551–583
- Guengerich F. P., Miller G. P., Hanna I. H., Sato H., Martin M. V. Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate‐limiting steps. J. Biol. Chem. 2002; 277: 33711–33719, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Guengerich F. P., Sorrells J. L., Schmitt S., Krauser J. A., Aryal P., Meijer L. Generation of new protein kinase inhibitors utilizing cytochrome P450 mutant enzymes for indigoid synthesis. J. Med. Chem. 2004, in press
- Gut J., Catin T., Dayer P., Kronbach T., Zanger U., Meyer U. A. Debrisoquine/sparteine‐type polymorphism of drug oxidation: purification and characterization of two functionally different human liver cytochrome P‐450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J. Biol. Chem. 1986; 261: 11734–11743, [PUBMED], [INFOTRIEVE]
- Hankinson O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 1995; 35: 307–340, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hansen B. T., Jones J. A., Mason D. E., Liebler D. C. SALSA: a pattern recognition algorithm to detect electrophile‐adducted peptides by automated evaluation of CID spectra in LC–MS–MS analyses. Anal. Chem. 2001; 73: 1676–1683, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hanzlik R. P., Tullman R. H. Suicidal inactivation of cytochrome P‐450 by cyclopropylamines. Evidence for cation‐radical intermediates. J. Am. Chem. Soc. 1982; 104: 2048–2050
- Hanzlik R. P., Kishore V., Tullman R. Cyclopropylamines as suicide substrates for cytochromes P‐450. J. Med. Chem. 1979; 22: 759–761, [PUBMED], [INFOTRIEVE]
- Harlow G. R., Halpert J. R. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site‐directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6636–6641, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Harris N., Cohen S., Filatov M., Ogliaro F., Shaik S. Two‐state reactivity in the rebound step of alkane hydroxylation by cytochrome P‐450: origins of free radicals with finite lifetimes. Angew. Chem. Int. Ed. Engl. 2000; 39: 2003–2007, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Haugen D. A., Coon M. J. Properties of electrophoretically homogenous phenobarbital‐inducible and β‐naphthoflavone‐inducible forms of liver microsomal cytochrome P‐450. J. Biol. Chem. 1976; 251: 7929–7939, [PUBMED], [INFOTRIEVE]
- Haugen D. A., van der Hoeven T. A., Coon M. J. Purified liver microsomal cytochrome P‐450: separation and characterization of multiple forms. J. Biol. Chem. 1975; 250: 3567–3570, [PUBMED], [INFOTRIEVE]
- Hayaishi O., Katagiri M., Rothberg S. Mechanism of the pyrocatechase reaction. J. Am. Chem. Soc. 1955; 77: 5450–5451
- Hildebrandt A., Estabrook R. W. Evidence for the participation of cytochrome b5 in hepatic microsomal mixed‐function oxidation reactions. Arch. Biochem. Biophys. 1971; 143: 66–79, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hildebrandt A., Remmer H., Estabrook R. W. Cytochrome P‐450 of liver microsomes: one pigment or many. Biochem. Biophys. Res. Commun. 1968; 30: 607–612, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hosea N. A., Miller G. P., Guengerich F. P. Elucidation of distinct binding sites for cytochrome P450 3A4. Biochemistry 2000; 39: 5929–5939, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hutzler J. M., Tracy T. S. Atypical kinetic profiles in drug metabolism reactions. Drug Metab. Dispos. 2002; 30: 355–362, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Imai M., Shimada H., Watanabe Y., Matsushima‐Hibiya Y., Makino R., Koga H., Horiuchi T., Ishimura Y. Uncoupling of the cytochrome P‐450cam monooxygenase reaction by a single mutation, threonine‐252 to alanine or valine: a possible role of the hydroxy amino acid in oxygen activation. Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 7823–7827, [PUBMED], [INFOTRIEVE], [CSA]
- Johnson K. A. Transient‐state kinetic analysis of enzyme reaction pathways. The Enzymes, P. D. Boyer. Academic Press, New York 1992; Vol. 20: 1–61
- Johnson E. F. The 2002 Bernard B. Brodie Award lecture: deciphering substrate recognition by drug‐metabolizing cytochromes P450. Drug Metab. Dispos. 2003; 31: 1532–1540, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kadkhodayan S., Coulter E. D., Maryniak D. M., Bryson T. A., Dawson J. H. Uncoupling oxygen transfer and electron transfer in the oxygenation of camphor analogues by cytochrome P450CAM: direct observation of an intermolecular isotope effect for substrate C–H activation. J. Biol. Chem. 1995; 270: 28042–28048, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kagawa N., Waterman M. R. Regulation of steroidogenic and related P450s. Cytochrome P450: Structure, Mechanism, and Biochemistry2nd ed., P. R. Ortiz de Montellano. Plenum Press, New York 1995; 419–442
- Kagawa N., Cao Q., Kusano K. Expression of human aromatase (CYP19) in Escherichia coli by N‐terminal replacement and induction of cold stress response. Steroids 2003; 68: 205–209, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kaminsky L. S., Guengerich F. P. Cytochrome P‐450 isozyme/isozyme functional interactions and NADPH‐cytochrome P‐450 reductase concentrations as factors in microsomal metabolism of warfarin. Eur. J. Biochem. 1985; 149: 479–489, [PUBMED], [INFOTRIEVE]
- Katagiri M., Ganguli B. N., Gunsalus I. C. A soluble cytochrome P450 functional in methylene hydroxylation. J. Biol. Chem. 1968; 243: 3543–3546, [PUBMED], [INFOTRIEVE]
- Kellerman G., Shaw C. R., Luyten‐Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. New Engl. J. Med. 1973; 298: 934–937
- Kim D., Guengerich F. P. Selection of human cytochrome P450 1A2 mutants with selectivity enhanced catalytic activity for heterocyclic amine N‐hydroxylation. Biochemistry 2004; 43: 981–988, [PUBMED], [INFOTRIEVE]
- Kimzey A. L., Weitz K. K., Guengerich F. P., Zanger R. C. Hydroperoxy‐10,12‐octadecadienoic acid stimulates cytochrome P450 3A protein aggregation by a mechanism that is inhibited by substrate. Biochemistry 2003; 42: 12691–12699, [PUBMED], [INFOTRIEVE]
- Kliewer S. A., Moore J. T., Wade L., Staudinger J. L., Watson M. A., Jones S. A., McKee D. D., Oliver B. B., Wilson T. M., Zetterstörm R. H., Perlmann T., Lehmann J. M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998; 92: 73–82, [PUBMED], [INFOTRIEVE]
- Korsmeyer K. K., Davoll S., Figueiredo‐Pereira M. E., Correia M. A. Proteolytic degradation of heme‐modified hepatic cytochromes P450: a role for phosphorylation, ubiquitination, and the 26S proteasome?. Arch. Biochem. Biophys. 1999; 365: 31–44, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Koshland D. E., Jr., Nemethy G., Filmer D. Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 1966; 5: 365–385, [PUBMED], [INFOTRIEVE]
- Krauser J. A., Guengerich F. P. Investigation of C—H bond cleavage by cytochrome P450 3A4. Abstract, TOX I 80, 226th Natl. Meet. Am. Chem. Soc. 2003, New York
- Lamb D. C., Skaug T., Song H.‐L., Jackson C. J., Podust L. M., Waterman M. R., Kell D. B., Kelly D. E., Kelly S. L. The cytochrome P450 complement (CYPome) of Streptomyces coelicolor A3(2). J. Biol. Chem. 2002; 277: 24000–24005, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lambeth J. D., Seybert D. W., Kamin H. Adrenodoxin reductase‐adrenodoxin complex: rapid formation and breakdown of the complex and a slow conformational change in the flavoprotein. J. Biol. Chem. 1980; 255: 4667–4672, [PUBMED], [INFOTRIEVE]
- Lang N. P., Butler M. A., Massengill J., Lawson M., Stotts R. C., Maurer‐Jensen M., Kadlubar F. F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food‐borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomark. Prev. 1994; 3: 675–682, [CSA]
- Lednicer D. Strategies for Organic Drug Synthesis and Design. John Wiley & Sons, New York 1998; 129–130
- Li H., Poulos T. L. Conformational dynamics in cytochrome P450‐substrate interactions. Biochimie 1996; 78: 695–699, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Loughran P. A., Roman L. J., Miller R. T., Masters B. S. S. The kinetic and spectral characterization of the E. coli‐expressed mammalian CYP4A7: cytochrome b5 effects vary with substrates. Arch. Biochem Biophys. 2001; 385: 311–321, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lu A. Y. H., Coon M. J. Role of hemoprotein P‐450 in fatty acid ω‐hydroxylation in a soluble enzyme system from liver microsomes. J. Biol. Chem. 1968; 243: 1331–1332, [PUBMED], [INFOTRIEVE]
- Lüdemann S. K., Lounnas V., Wade R. C. How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanism. J. Mol. Biol. 2000; 303: 797–811, [CROSSREF]
- Macdonald T. L., Zirvi K., Burka L. T., Peyman P., Guengerich F. P. Mechanism of cytochrome P‐450 inhibition by cyclopropylamines. J. Am. Chem. Soc. 1982; 104: 2050–2052
- Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; ii: 584–586, [CROSSREF]
- Marques‐Soares C., Dijols S., Macherey A.‐C., Wester M. R., Johnson E. F., Dansette P. M., Mansuy D. Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochrome P450 2Cs: identification of a new high affinity substrate common to those CYP 2C enzymes. Biochemistry 2003; 42: 6363–6369, [CROSSREF]
- Martinis S. A., Atkins W. M., Stayton P. S., Sligar S. G. A conserved residue of cytochrome P‐450 is involved in heme‐oxygen stability and activation. J. Am. Chem. Soc. 1989; 111: 9252–9253
- Mason H. S. Mechanisms of oxygen metabolism. Science 1957; 125: 1185–1190, [PUBMED], [INFOTRIEVE]
- Maxam A. M., Gilbert W. A new method for sequencing DNA. Proc. Natl. Acad. Sci. U. S. A. 1977; 74: 560–564, [PUBMED], [INFOTRIEVE]
- Mico B. A., Swagzdis J. E., Hu H. S.‐W., Keefer L. K., Oldfield N. F., Garland W. A. Low‐dose in vivo pharmacokinetic and deuterium isotope effect studies of N‐nitrosodimethylamine in rats. Cancer Res. 1985; 45: 6280–6285, [PUBMED], [INFOTRIEVE]
- Miller W. L. Congenital adrenal hyperplasia. New Engl. J. Med. 1986; 314: 1321–1322, [PUBMED], [INFOTRIEVE]
- Miller G. P., Guengerich F. P. Binding and oxidation of alkyl 4‐nitrophenyl ethers by rabbit cytochrome P450 1A2: evidence for two binding sites. Biochemistry 2001; 40: 7262–7272, [PUBMED], [INFOTRIEVE]
- Miller E. C., Miller J. A., Brown R. R., MacDonald J. C. On the protective action of certain polycyclic aromatic hydrocarbons against carcinogenesis by aminoazo dyes and 2‐acetylaminofluorene. Cancer 1958; Res.18: 469–477
- Mueller G. C., Miller J. A. The metabolism of 4‐dimethylaminoazobenzene by rat liver homogenates. J. Biol. Chem. 1948; 176: 535–544
- Mueller E. J., Loida P. J., Sligar S. G. Twenty‐five years of P450cam reseach: mechanistic insights into oxygenase catalysis. Cytochrome P450: Structure, Mechanism, and Biochemistry2nd ed., P. R. Ortiz de Montellano. Plenum Press, New York 1995; 83–124
- Nagata K., Yamazoe Y. Genetic polymorphism of human cytochrome P450 involved in drug metabolism. Drug Metab. Pharmacokinet. 2002; 17: 167–189, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nakayama N., Takemae A., Shoun H. Cytochrome P450foxy, a catalytically self‐sufficient fatty acid hydroxylase of the fungus Fusarium oxysporum. J. Biochem. (Tokyo) 1996; 119: 435–440
- Nebert D. W. Multiple forms of inducible drug‐metabolizing enzymes: a reasonable mechanism by which any organism can cope with adversity. Mol. Cell. Biochem. 1979; 27: 27–46, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nebert D. W. The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. CRC Crit. Rev. Toxicol. 1989; 20: 153–174
- Nebert D. W., Gelboin H. V. Substrate‐inducible microsomal aryl hydroxylase in mammalian cell culture. II. Cellular responses during enzyme induction. J. Biol. Chem. 1968; 243: 6250–6261, [PUBMED], [INFOTRIEVE]
- Nebert D. W., Russell D. W. Clinical importance of the cytochromes P450. Lancet 2002; 360: 1155–1162, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nelson D. R. Comparison of P450s from human and fugu: 420 million years of vertebrate P450 evolution. Arch. Biochem. Biophys. 2003; 409: 18–24, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nelson D. R., Koymans L., Kamataki T., Stegeman J. J., Feyereisen R., Waxman D. J., Waterman M. R., Gotoh O., Coon M. J., Estabrook R. W., Gunsalus I. C., Nebert D. W. P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 1996; 6: 1–42, [PUBMED], [INFOTRIEVE], [CSA]
- Newcomb M., Le Tadic‐Biadatti M. H., Chestney D. L., Roberts E. S., Hollenberg P. F. A nonsynchronous concerted mechanism for cytochrome P‐450 catalyzed hydroxylation. J. Am. Chem. Soc. 1995; 117: 12085–12091
- Newcomb M., Aebisher D., Shen R., Chandrasena R. E., Hollenberg P. F., Coon M. J. Kinetic isotope effects implicate two electrophilic oxidants in cytochrome P450‐catalyzed hydroxylations. J. Am. Chem. Soc. 2003; 125: 6064–6065, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ngui J. S., Tang W., Stearns R. A., Shou M. G., Miller R. R., Zhang Y., Lin J. H., Baillie T. A. Cytochrome P450 3A4‐mediated interaction of diclofenac and quinidine. Drug Metab. Dispos. 2000; 28: 1043–1050, [PUBMED], [INFOTRIEVE], [CSA]
- Niranjan B. G., Wilson N. M., Jefcoate C. R., Avadhani N. G. Hepatic mitochondrial cytochrome P‐450 system: distinctive features of cytochrome P‐450 involved in the activation of aflatoxin B1 and benzo(a)pyrene. J. Biol. Chem. 1984; 259: 12495–12501, [PUBMED], [INFOTRIEVE]
- Northrop D. B. Steady‐state analysis of kinetic isotope effects in enzymic reactions. Biochemistry 1975; 14: 2644–2651, [PUBMED], [INFOTRIEVE]
- Northrop D. B. Deuterium and tritium kinetic isotope effects on initial rates. Methods Enzymol. 1982; 87: 607–625, [PUBMED], [INFOTRIEVE]
- Northrop D. B. On the meaning of Km and V/K in enzyme kinetics. J. Chem. Ed. 1998; 75: 1153–1157
- Omura T., Sato R. A new cytochrome in liver microsomes. J. Biol. Chem. 1962; 237: 1375–1376, [PUBMED], [INFOTRIEVE]
- Ortiz de Montellano P. R. Oxygen activation and reactivity. Cytochrome P450: Structure, Mechanism, and Biochemistry2nd ed., P. R. Ortiz de Montellano. Plenum Press, New York 1995; 245–303
- Ortiz de Montellano P. R. Cytochrome P450: Structure, Mechanism, and Biochemistry3rd ed., P. R. Ortiz de Montellano. Plenum Press, New York 2004, in press
- Ortiz de Montellano P. R., Stearns R. A. Timing of the radical recombination step in cytochrome P‐450 catalysis with ring‐strained probes. J. Am. Chem. Soc. 1987; 109: 3415–3420
- Parikh A., Josephy P. D., Guengerich F. P. Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties. Biochemistry 1999; 38: 5283–5289, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Peterson J. A., Graham‐Lorence S. E. Bacterial P450s: Structural similarities and functional differences. Cytochrome P450: Structure, Mechanism, and Biochemistry2nd ed., P. R. Ortiz de Montellano. Plenum Press, New York 1995; 151–180
- Podust L. M., Poulos T. L., Waterman M. R. Crystal structure of cytochrome P450 14α‐sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 3068–3073, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Poland A., Glover E., Kende A. S. Stereospecific, high affinity binding of 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem. 1976; 251: 4936–4946, [PUBMED], [INFOTRIEVE]
- Pompon D., Coon M. J. On the mechanism of action of cytochrome P‐450: oxidation and reduction of the ferrous dioxygen complex of liver microsomal cytochrome P‐450 by cytochrome b5. J. Biol. Chem. 1984; 259: 15377–15385, [PUBMED], [INFOTRIEVE]
- Poulos T. P. Cytochrome P450: molecular architecture, mechanism, and prospects for rational inhibitor design. Pharm. Res. 1988; 5: 67–75, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Poulos T. L., Finzel B. C., Gunsalus I. C., Wagner G. C., Kraut J. The 2.6‐Å crystal structure of Pseudomonas putida cytochrome P‐450. J. Biol. Chem. 1985; 260: 16122–16130, [PUBMED], [INFOTRIEVE]
- Poulos T. L., Finzel B. C., Howard A. J. High‐resolution crystal structure of cytochrome P450cam. J. Mol. Biol. 1987; 195: 687–700, [PUBMED], [INFOTRIEVE]
- Poulos T. L., Cupp‐Vickery J., Li H. Y. Structural studies on prokaryotic cytochromes P450. Cytochrome P450: Structure, Mechanism, and Biochemistry2nd ed., P. R. Ortiz de Montellano. Plenum Press, New York 1995; 125–150
- Raag R., Poulos T. L. The structural basis for substrate‐induced changes in redox potential and spin equilibrium in cytochrome P‐450CAM. Biochemistry 1989; 28: 917–922, [PUBMED], [INFOTRIEVE]
- Raag R., Poulos T. L. Crystal structures of cytochrome P‐450CAM complexed with camphane, thiocamphor and adamatane: factors controlling P‐450 substrate hydroxylation. Biochemistry 1991; 30: 2674–2684, [PUBMED], [INFOTRIEVE]
- Remmer H. The acceleration of evipan oxidation and the demethylation of methylaminopyrine by barbiturates. Naunyn‐Schmiedeberg's Arch. Exp. Pathol. Pharmakol. 1957; 237: 296–307
- Richardson H. L., Stier A. R., Borsos‐Nachtnebel E. Liver tumor inhibition and adrenal histologic responses in rats to which 3′‐methyl‐4‐dimethylaminoazobenzene and 20‐methylcholanthrene were simultaneously administered. Cancer Res. 1952; 12: 356–361, [PUBMED], [INFOTRIEVE]
- Ritchie J. C., Sloan T. P., Idle J. R., Smith R. L. Toxicological implications of polymorphic drug metabolism. Environmental Chemicals, Enzyme Function and Human Disease (Ciba Foundation Symposium 76). Excerpta Medica, New York 1980; 219–244
- Roberts G. A., Celik A., Hunter D. J., Ost T. W., White J. H., Chapman S. K., Turner N. J., Flitsch S. L. A self‐sufficient cytochrome P450 with a primary structural organization that includes a flavin domain and a [2Fe–2S] redox center. J. Biol. Chem. 2003; 278: 48914–48920, [PUBMED], [INFOTRIEVE]
- Russell D. W. Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta 2000; 1529: 126–135, [PUBMED], [INFOTRIEVE]
- Ryan K. J. Conversion of androstenedione to estrone by placental microsomes. Biochim. Biophys. Acta 1958; 27: 658–662, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain‐terminatiing inhibitors. Proc. Natl. Acad. Sci. U. S. A. 1977; 74: 5463–6467, [PUBMED], [INFOTRIEVE]
- Schlichting I., Berendzen J., Chu K., Stock A. M., Maves S. A., Benson D. E., Sweet B. M., Ringe D., Petsko G. A., Sligar S. G. The catalytic pathway of cytochrome P450cam at atomic resolution. Science 2000; 287: 1615–1622, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Schoch G. A., Yano J. K., Wester M. R., Griffin K. J., Stout C. D., Johnson E. F. Structure of human microsomal cytochrome P450 2C8: evidence for a peripheral fatty acid binding site. J. Biol. Chem. 2004; 279, in press, [CROSSREF]
- Schuler M. A. The role of cytochrome P450 monooxygenases in plant–insect interactions. Plant Physiol. 1996; 112: 1411–1419, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Scott E. E., He Y. Q., Halpert J. R. Substrate routes to the buried active site may vary among cytochromes P450: mutagenesis of the F–G region in P450 2B1. Chem. Res. Toxicol. 2002; 15: 1407–1413, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Scott E. E., He Y. A., Wester M. R., White M. A., Chin C. C., Halpert J. R., Johnson E. F., Stout C. D. An open conformation of mammalian cytochrome P450 2B4 at 1.6—a resolution. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 13196–13201, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Segel I. H. Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady‐State Enzyme Systems. John Wiley & Sons, New York 1975
- Serizawa N., Nakagawa K., Hamano K., Tsujita Y., Terahara A., Kuwano H. Microbial hydroxylation of ML‐236B (compactin) and monacolin K (MB‐530B). J. Antibiot. 1983; 36: 604–607, [PUBMED], [INFOTRIEVE]
- Shaik S., de Visser S. P., Ogliaro F., Schwarz H., Schroder D. Two‐state reactivity mechanisms of hydroxylation and epoxidation by cytochrome P‐450 revealed by theory. Curr. Opin. Chem. Biol. 2002; 6: 556–567, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sheldon R. A., Kochi J. K. Activation of molecular oxygen by metal complexes. Metal‐Catalyzed Oxidations of Organic Compounds. Academic Press, New York 1981; 108–112
- Shimada T., Hayes C. L., Yamazaki H., Amin S., Hecht S. S., Guengerich F. P., Sutter T. R. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res. 1996; 56: 2979–2984, [PUBMED], [INFOTRIEVE]
- Shimozawa O., Sakaguchi M., Ogawa H., Harada N., Mihara K., Omura T. Core glycosylation of cytochrome P450(arom). Evidence for localization of N terminus of microsomal cytochrome P‐450 in the lumen. J. Biol. Chem. 1993; 268: 21399–21402, [PUBMED], [INFOTRIEVE]
- Shou M., Grogan J., Mancewicz J. A., Krausz K. W., Gonzalez F. J., Gelboin H. V., Korzekwa K. R. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33: 6450–6455, [PUBMED], [INFOTRIEVE]
- Shou M., Dai R., Cui D., Korzekwa K. R., Baillie T. A., Rushmore T. H. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J. Biol. Chem. 2001; 276: 2256–2262, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Skoda R. C., Gonzalez F. J., Demierre A., Meyer U. A. Two mutant alleles of the human cytochrome P‐450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 5240–5243, [PUBMED], [INFOTRIEVE], [CSA]
- Sladek N. E., Mannering G. J. Induction of drug metabolism. II. Qualitative differences in the microsomal N‐demethylating systems stimulated by polycyclic hydrocarbons and by phenobarbital. Mol. Pharmacol. 1969; 5: 186–199, [PUBMED], [INFOTRIEVE]
- Smith R. L. Polymorphism in drug metabolism‐implications for drug toxicity. Arch. Toxicol. 1986; Supplement. 9: 138–146
- Smith D. A., Jones B. C. Speculations on the substrate structure‐activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol. 1992; 44: 2089–2098, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Staudinger J. L., Goodwin B., Jones S. A., Hawkins‐Brown D., MacKenzie K. I., LaTour A., Liu Y., Klaassen C. D., Brown K. K., Reinhard J., Willson T. M., Koller B. H., Kliewer S. A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 3369–3374, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Stearns R. A., Ortiz de Montellano P. R. Cytochrome P‐450 catalyzed oxidation of quadricyclane. Evidence for a radical cation intermediate. J. Am. Chem. Soc. 1985; 107: 4081–4082
- Strobel H. W., Coon M. J. Effect of superoxide generation and dismutation on hydroxylation reactions catalyzed by liver microsomal cytochrome P‐450. J. Biol. Chem. 1971; 246: 7826–7829, [PUBMED], [INFOTRIEVE]
- Tirona R. G., Lee W., Leake B. F., Lan L. B., Cline C. B., Lamba V., Parviz F., Duncan S. A., Inoue Y., Gonzalez F. J., Schuetz E. G., Kim R. B. The orphan nuclear receptor HNF4α determines PXR‐ and CAR‐mediated xenobiotic induction of CYP3A4. Nat. Med. 2003; 9: 220–224, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Toide K., Yamazaki H., Nagashima R., Itoh K., Iwano S., Takahashi Y., Watanabe S., Kamataki T. Aryl hydrocarbon hydroxylase represents CYP1B1, and not CYP1A1, in human freshly isolated white cells: trimodal distribution of Japanese population according to induction of CYP1B1 mRNA by environmental dioxins. Cancer Epidemiol. Biomarkers Prev. 2003; 12: 219–222, [PUBMED], [INFOTRIEVE]
- Tosha T., Yoshioka S., Takahashi S., Ishimori K., Shimada H., Morishima I. NMR study on the structural changes of cytochrome P450cam upon the complex formation with putidaredoxin. Functional significance of the putidaredoxin‐induced structural changes. J. Biol. Chem. 2003; 278: 39809–39821, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Toy P. H., Newcomb M., Hollenberg P. F. Hypersenstive mechanistic probe studies of cytochrome P450‐catalyzed hydroxylation reactions. Implications for the cationic pathway. J. Am. Chem. Soc. 1998; 120: 7719–7729, [CROSSREF]
- Tyson C. A., Lipscomb J. D., Gunsalus I. C. The roles of putidaredoxin and P450cam in methylene hydroxylation. J. Biol. Chem. 1972; 247: 5777–5784, [PUBMED], [INFOTRIEVE]
- Ueng Y.‐F., Kuwabara T., Chun Y.‐J., Guengerich F. P. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997; 36: 370–381, [PUBMED], [INFOTRIEVE], [CROSSREF]
- van Breemen R. B., Nikolic D., Bolton J. L. Metabolic screening using on‐line ultrafiltration mass spectrometry. Drug Metab. Dispos. 1998; 26: 85–90, [PUBMED], [INFOTRIEVE], [CSA]
- Vaz A. D. N., Kessell K. J., Coon M. J. Aromatization of a bicyclic steroid analog, 3‐oxodecalin‐4‐ene‐10‐carboxaldehyde, by liver microsomal cytochrome P450 2B4. Biochemistry 1994; 33: 13651–13661, [PUBMED], [INFOTRIEVE]
- Voznesensky A. I., Schenkman J. B. Quantitative analyses of electrostatic interactions between NADPH‐cytochrome P450 reductase and cytochrome P450 enzymes. J. Biol. Chem. 1994; 269: 15724–15731, [PUBMED], [INFOTRIEVE]
- Walsh C. Enzymatic Reaction Mechanisms. W.H. Freeman, San Francisco 1979
- Waxman D. J. Minireview. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 1999; 369: 11–23, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wester M. R., Johnson E. F., Marques‐Soares C., Dansette P., Mansuy D., Stout C. D. The structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution: evidence for multiple substrate binding modes. Biochemistry 2003a; 42: 6370–6379, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wester M. R., Johnson E. F., Marques‐Soares C., Dijols S., Dansette P. M., Mansuy D., Stout C. D. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 Å resolution: evidence for an induced fit model of substrate binding. Biochemistry 2003b; 42: 9335–9345, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wester M. R., Stout C. D., Schoch G., Yano J. K., Johnson E. F. Crystallization of human P450 2C9. FASEB J. 2003c; 17: A609
- Williams R. T. Detoxication Mechanisms1st ed. Wiley, London 1947
- Williams P. A., Cosme J., Sridhar V., Johnson E. F., MeRee D. E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell. 2000; 5: 121–131, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Williams P. A., Cosme J., Ward A., Angove H. C., Matak Vinkovic D., Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003; 424: 464–468, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Winn P. J., Lüdemann S. K., Gauges R., Lounnas V., Wade R. C. Comparison of the dynamics of substrate access channels in three cytochrome P450s reveals different opening mechanisms and a novel functional role for a buried arginine. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 5361–5366, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wiseman T., Williston S., Brandts J. F., Lin L. N. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 1989; 179: 131–137, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Witherow L. E., Houston J. B. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J. Pharmacol. Exp. Ther. 1999; 290: 58–65, [PUBMED], [INFOTRIEVE], [CSA]
- Yamazaki H., Johnson W. W., Ueng Y.‐F., Shimada T., Guengerich F. P. Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4: characterization of a reconstituted cytochrome P450 3A4/NADPH‐cytochrome P450 reductase system and studies with apo‐cytochrome b5. J. Biol. Chem. 1996a; 271: 27438–27444, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yamazaki H., Nakano M., Imai Y., Ueng Y.‐F., Guengerich F. P., Shimada T. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch. Biochem. Biophys. 1996b; 325: 174–182, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yamazaki H., Gillam E. M. J., Dong M.‐S., Johnson W. W., Guengerich F. P., Shimada T. Reconstitution of recombinant human cytochrome P450 2C9 and comparison with cytochrome P450 and other forms: effects of cytochrome P450:P450 and cytochrome P450:b5 interactions. Arch. Biochem. Biophys. 1997; 342: 329–337, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yamazaki H., Komatsu T., Ohyama K., Nakamura M., Asahi S., Shimada N., Guengerich F. P., Nakajima A., Yokoi T. Roles of NADPH‐P450 reductase and apo‐ and holo‐cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Express. Purif. 2002; 24: 329–337, [CROSSREF], [CSA]
- Yong F. C., King T. E., Oldham S., Waterman M. R., Mason H. S. Redox‐dependent conformational changes of rabbit liver cytochrome P‐450. Arch. Biochem. Biophys. 1970; 138: 96–100, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yun C.‐H., Miller G. P., Guengerich F. P. Rate‐determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 2000; 39: 11319–11329, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yun C.‐H., Miller G. P., Guengerich F. P. Oxidations of p‐alkoxyacylanilides by human cytochrome P450 1A2: structure‐activity relationships and simulation of rate constants of individual steps in catalysis. Biochemistry 2001; 40: 4521–4530, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zerbe K., Pylypenko O., Vitali F., Zhang W., Rouset S., Heck M., Vrijbloed J. W., Bischoff D., Bister B., Sussmuth R. D., Pelzer S., Wohlleben W., Robinson J. A., Schlichting I. Crystal structure of OxyB, a cytochrome P450 implicated in an oxidative phenol coupling reaction during vancomycin biosynthesis. J. Biol. Chem. 2002; 277: 47476–47485, [PUBMED], [INFOTRIEVE], [CROSSREF]